New Onset Diabetes and Impaired Fasting Glucose After Liver Transplant: Risk Analysis and the Impact of Tacrolimus Dose

2014 ◽  
Vol 12 (1) ◽  
pp. 46-51 ◽  
Author(s):  
Kamran Bagheri Lankarani ◽  
◽  
Ahad Eshraghian ◽  
Saman Nikeghbalian ◽  
Parisa Janghorban ◽  
...  
Keyword(s):  
Risk Analysis ◽  
Liver Transplant ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Onset Diabetes ◽  
The Impact ◽  
Tacrolimus Dose ◽  
New Onset

scholarly journals Predicting New Onset Diabetes Mellitus in Older Taiwanese: Metabolic Syndrome or Impaired Fasting Glucose?

2009 ◽  
Vol 16 (5) ◽  
pp. 627-632 ◽  
Author(s):  
Liang-Kung Chen ◽  
Li-Ning Peng ◽  
Ming-Hsien Lin ◽  
Hsiu-Yun Lai ◽  
Shinn-Jang Hwang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Onset Diabetes ◽  
New Onset Diabetes Mellitus ◽  
New Onset

scholarly journals Study of New onset Diabetes Mellitus in Acute Coronary Syndrome Patients

2018 ◽  
Vol 3 (1) ◽  
Keyword(s):  
Acute Coronary Syndrome ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Clinical Status ◽  
Limited Information ◽  
Coronary Syndrome ◽  
Onset Diabetes ◽  
New Onset

Introduction: There is limited information on the incidence of diabetes despite INDIA being the Global capital for Diabetes. Though much of data is available in patients already diagnosed with diabetes but data regarding the new onset diabetes in the subset of Acute coronary syndrome (ACS) is very limited. Materials and methods: This was a Cohort study in which 200 consecutive ACS patients were included. Lab data about their FBS; PPBS; Lipid profile & Hba1c, BMI, BP and their clinical status was collected at the time of admission, after discharge at 2 weeks, 6 weeks & 3,6 & 12 months post ACS. Results: In study 85% were males. Mean age was 56 years. Prevalence of various atherosclerotic risk factors in study population matched the regional prevalence of them. 20% (n=40) developed New onset diabetes (NOD), 2.5% (n=5) developed Impaired fasting Glucose, 6% (n=12) developed Impaired glucose tolerance in and 1.5% (n=3) developed both Impaired fasting glucose and Impaired Glucose tolerance over a follow up period of 1 year. MACE rates & Revascularisation rates were significantly higher in NOD population. NOD patients had significantly higher BMI, waist circumference, BP, TG, LDL and Low HDL. NOD patients were on Higher dosage of statins, diuretics and Beta blockers. Conclusion: The study highlights two important things, first incidence of new onset diabetes in acute coronary syndrome patients is High, second new onset diabetes has a significant impact on the clinical outcome of ACS patients

scholarly journals Adipose Triglyceride Lipase Single Nucleotide Polymorphism is Associated with Heart Failure Development after Acute Myocardial Infarction in Patients with Dyslipidemia

2018 ◽  
Vol 3 (1) ◽  
Keyword(s):  
Acute Coronary Syndrome ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Clinical Status ◽  
Limited Information ◽  
Coronary Syndrome ◽  
Onset Diabetes ◽  
New Onset

Introduction: There is limited information on the incidence of diabetes despite INDIA being the Global capital for Diabetes. Though much of data is available in patients already diagnosed with diabetes but data regarding the new onset diabetes in the subset of Acute coronary syndrome (ACS) is very limited. Materials and methods: This was a Cohort study in which 200 consecutive ACS patients were included. Lab data about their FBS; PPBS; Lipid profile & Hba1c, BMI , BP and their clinical status was collected at the time of admission, after discharge at 2 weeks, 6 weeks & 3,6 & 12 months post ACS. Results: In study 85% were males. Mean age was 56 years. Prevalence of various atherosclerotic risk factors in study population matched the regional prevalence of them. 20% (n=40) developed New onset diabetes (NOD), 2.5% (n=5) developed Impaired fasting Glucose, 6% (n=12) developed Impaired glucose tolerance in and 1.5% (n=3) developed both Impaired fasting glucose and Impaired Glucose tolerance over a follow up period of 1 year. MACE rates & Revascularisation rates were significantly higher in NOD population. NOD patients had significantly higher BMI, waist circumference, BP, TG, LDL and Low HDL. NOD patients were on Higher dosage of statins, diuretics and Beta blockers. Conclusion: The study highlights two important things, first incidence of new onset diabetes in acute coronary syndrome patients is High, Second new onset diabetes has a significant impact on the clinical outcome of ACS patients

scholarly journals Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Elizabeth J. Carey ◽  
Bashar A. Aqel ◽  
Thomas J. Byrne ◽  
David D. Douglas ◽  
Jorge Rakela ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Transplant ◽  
Fasting Glucose ◽  
Meld Score ◽  
Transplant Recipients ◽  
Onset Diabetes ◽  
The Mean ◽  
One Year ◽  
Liver Transplant Recipients ◽  
New Onset

New-onset diabetes after transplantation (NODAT) is common after liver transplant and associated with poorer outcomes. The aim of this study was to identify risk factors for NODAT in liver transplant recipients off corticosteroids. In 225 adult nondiabetic liver transplant recipients, the mean age was 51.7 years, the majority were men (71%), and half had HCV (49%). The mean calculated MELD score at transplantation was 18.7, and 19% underwent living-donor transplant (LDLT). One year after transplantation, 17% developed NODAT, and an additional 16% had impaired fasting glucose. The incidence of NODAT in patients with HCV was 26%. In multivariate analysis, HCV, pretransplant FPG, and LDLT were significant. Each 10 mg/dL increase in pretransplant FPG was associated with a twofold increase in future development of NODAT. The incidence of NODAT after liver transplant in patients off corticosteroids is 17%. Risk factors for developing NODAT include HCV and pretransplant FPG; LDLT is protective.

Sign in / Sign up

Export Citation Format

Share Document